



**NMS Labs**

**CONFIDENTIAL**

200 Welsh Road, Horsham, PA 19044-2208  
Phone: (215) 657-4900 Fax: (215) 657-2972  
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

**Demo Report**

**Report Issued** 04/21/2022 18:07  
**Last Report Issued** 02/09/2012 08:04

**88888**  
Clinical Example Report  
Attn: Example Reports  
200 Welsh Road  
Horsham, PA 19044

**Patient Name** 3075SP-POS  
**Patient ID** 3075SP-POS  
**Chain** 12000320  
**DOB** Not Given  
**Sex** Not Given  
**Workorder** 12000320  
**Received** 02/09/2012

**Lab ID** 12000320-001  
**Matrix** Serum  
**Patient Name** 3075SP-POS  
**Patient ID** 3075SP-POS  
**Container Type** Clear vial

**Collect Dt/Tm** Not Given  
**Source** Not Given

**Approx Vol/Weight** Not Given

**Receipt Notes** None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

**3075SP Mirtazapine, Serum/Plasma**

Analysis by Gas Chromatography (GC)

Mirtazapine	5000	ng/mL	5.0	ELEVATED
-------------	------	-------	-----	----------

Synonym(s): Remeron®

Steady-state peak (0.7 to 4.8 hours post-dose) and trough plasma concentrations following a daily regimen:  
15 mg/day: 27 - 51 ng/mL peak; 4.3 - 12 ng/mL trough  
30 mg/day: 56 - 104 ng/mL peak; 11 - 25 ng/mL trough  
45 mg/day: 84 - 142 ng/mL peak; 17 - 39 ng/mL trough  
60 mg/day: 117 - 199 ng/mL peak; 24 - 52 ng/mL trough  
75 mg/day: 137 - 225 ng/mL peak; 28 - 64 ng/mL trough

Elimination half-life: 20 to 40 hours.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.